Search clinical trials for: tocilizumab [RoActemra/Actemra] Syringe

Total 282 results

Hoffmann-La Roche

Completed

A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers

Healthy Volunteer

France
Syneos Health
Dr. Reddy's Laboratories Limited

Completed

Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers

Rheumatoid Arthritis | Giant Cell Arteritis

New Zealand, Australia, India
Hoffmann-La Roche

Completed

A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)

Rheumatoid Arthritis

Kazakhstan
Hoffmann-La Roche

Completed

An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Russian Federation
Hoffmann-La Roche

Completed

A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Brazil
Hoffmann-La Roche

Terminated

An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

Russian Federation, Poland
Hoffmann-La Roche

Completed

A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs

Rheumatoid Arthritis

Finland
Hoffmann-La Roche

Completed

A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA) (JIGSAW 117)

Juvenile Idiopathic Arthritis

Spain, Mexico, Germany, United States, Russian Federation, Australia, Italy, Argentina, Brazil, Canada, France, United Kingdom
Hoffmann-La Roche

Completed

A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study

Juvenile Idiopathic Arthritis

France
Hoffmann-La Roche

Completed

An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study

Juvenile Idiopathic Arthritis

Brazil
Hoffmann-La Roche

Completed

An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.

Rheumatoid Arthritis

Belgium, Czech Republic, France, Italy, Spain, Sweden, United Kingdom, Canada, Greece, Ireland, Portugal, Turkey, Netherlands, Denmark, Finland, Germany, Luxembourg, Austria, Switzerland, Poland, Australia, Hungary, Saudi Arabia, Romania and more
Hoffmann-La Roche

Completed

A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

Rheumatoid Arthritis

United Arab Emirates, Kuwait, Bahrain, Iran, Islamic Republic of, Qatar
Hoffmann-La Roche

Completed

A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

United States, Canada, United Kingdom, Brazil, Argentina, Germany, Italy, Russian Federation, Spain, Mexico, Australia, France
Hoffmann-La Roche

Completed

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF

Rheumatoid Arthritis

Saudi Arabia
Hoffmann-La Roche

Completed

A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Philippines
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.

Rheumatoid Arthritis

Israel
Hoffmann-La Roche

Completed

A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).

Rheumatoid Arthritis

France
Hoffmann-La Roche

Completed

A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis

Rheumatoid Arthritis

Hungary
Hoffmann-La Roche

Completed

A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study

Juvenile Idiopathic Arthritis

Germany
Hoffmann-La Roche

Completed

A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis

Rheumatoid Arthritis

Spain
Hoffmann-La Roche

Completed

Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine

Rheumatoid Arthritis

Germany
Genentech, Inc.

Completed

A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.

Rheumatoid Arthritis

United Kingdom
Hoffmann-La Roche

Completed

A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Spain
Hoffmann-La Roche

Completed

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)

Rheumatoid Arthritis

Morocco
Hoffmann-La Roche

Completed

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

United States, Canada, United Kingdom, Brazil, Germany, Italy, Russian Federation, Spain, Australia, France, Mexico, Argentina
Hoffmann-La Roche

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).

Giant Cell Arteritis

Switzerland
Hoffmann-La Roche

Terminated

A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Poland
Hoffmann-La Roche

Completed

TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment

Rheumatoid Arthritis

Belgium, Luxembourg
Hoffmann-La Roche
Clalit Health Services

Completed

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS

Rheumatoid Arthritis

Israel
Hoffmann-La Roche

Completed

A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926

Rheumatoid Arthritis

Macedonia, The Former Yugoslav Republic of
Hoffmann-La Roche

Completed

A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment

Castleman's Disease

United States
Hoffmann-La Roche

Completed

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Turkey
Hoffmann-La Roche

Completed

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Rheumatoid Arthritis

Denmark, Iceland
Hoffmann-La Roche

Completed

An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy

Rheumatoid Arthritis

Czech Republic, France, Italy, Spain, United Kingdom, Canada, Portugal, Netherlands, Poland, Australia, Saudi Arabia, Romania, Hungary, Greece
Assistance Publique - Hôpitaux de Paris
Roche Pharma AG; Roche Chugai

Recruiting

Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement (TOGIAC)

Giant Cell Arteritis | Neurovascular Disorder

France
Hoffmann-La Roche

Completed

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

Juvenile Idiopathic Arthritis

Belgium, Canada, United States, Argentina, Poland, Spain, Germany, Hungary
Hoffmann-La Roche

Completed

A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.

Rheumatoid Arthritis

China
Hoffmann-La Roche

Completed

A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

France
Hoffmann-La Roche

Completed

An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Rheumatoid Arthritis

Australia
Hoffmann-La Roche

Terminated

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Renal Cell Carcinoma | Colorectal Cancer | Pancreatic Adenocarcinoma | Ovarian Neoplasms | Non-small Cell Lung Cancer

United States
Hoffmann-La Roche

Completed

A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

Rheumatoid Arthritis

Spain, China, United States, France, Sweden, South Africa, Czech Republic, Australia, Germany, Russian Federation, Canada, Thailand, Mexico, Hong Kong, Brazil, Argentina, Panama, Costa Rica, Finland
Hoffmann-La Roche

Completed

A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

Sclerosis, Systemic

Germany, United States, France, United Kingdom, Canada
Hoffmann-La Roche

Completed

A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose RoActemra/Actemra (Tocilizumab) in Healthy Volunteers

Healthy Volunteer

United Kingdom
Biogen

Recruiting

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

Healthy Volunteer

United States
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

Australia, Spain, Israel, Korea, Republic of, Greece, Norway, Denmark
Hoffmann-La Roche

Completed

A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs

Rheumatoid Arthritis

Portugal
Genentech, Inc.

Recruiting

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Multiple Myeloma

United States, Canada, Spain, Australia
Hoffmann-La Roche

Completed

A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

Juvenile Idiopathic Arthritis

Canada, Mexico, United States, Argentina, Germany, Israel, Italy, Russian Federation, Spain, United Kingdom
Genentech, Inc.

Recruiting

A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

Australia

3

Subscribe